QQ客服 官方微博 反馈留言

	Combination of 131I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma
	Duan C.; Li Y.; Yang W.; Zhang C.
刊名	Biotechnology and Biotechnological Equipment
	2018
页码	1-8
关键词	131I 5-fluorouracil antiangiogenic therapy combination therapy endgolin hepatocellular carcinoma radioimmunotherapy
DOI	10.1080/13102818.2018.1475254
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4583245
专题	山东大学
作者单位	The Laboratory Center for Basic Medicine and Biomedical Isotope Research Center, School of Basic Medical Science, Shandong University, Jinan
推荐引用方式 GB/T 7714	Duan C.,Li Y.,Yang W.,et al. Combination of 131I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma[J]. Biotechnology and Biotechnological Equipment,2018:1-8.
APA	Duan C.,Li Y.,Yang W.,&Zhang C..(2018).Combination of 131I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma.Biotechnology and Biotechnological Equipment,1-8.
MLA	Duan C.,et al."Combination of 131I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma".Biotechnology and Biotechnological Equipment (2018):1-8.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。